Synthesis and SAR of azolopyrimidines as potent and selective dipeptidyl peptidase-4 (DPP4) inhibitors for type 2 diabetes

Bioorganic and Medicinal Chemistry Letters

Volumn 20, Issue 15, 2010, Pages 4395-4398

  Brigance, Robert P ^a   Meng, Wei ^a   Fura, Aberra ^a   Harrity, Thomas ^a   Wang, Aiying ^a   Zahler, Robert ^a   Kirby, Mark S ^a   Hamann, Lawrence G ^a  

^a BRISTOL MYERS SQUIBB   (United States)

Author keywords

Azolopyrimidines; DPP4; GLP 1; SAR

Indexed keywords

ALOGLIPTIN; AZOLOPYRIMIDINE; DIPEPTIDYL PEPTIDASE IV INHIBITOR; LINAGLIPTIN; SAXAGLIPTIN; SITAGLIPTIN; UNCLASSIFIED DRUG; VILDAGLIPTIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; DRUG POTENCY; DRUG SELECTIVITY; DRUG SYNTHESIS; MOUSE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; STRUCTURE ACTIVITY RELATION;

DIABETES MELLITUS, TYPE 2; DIPEPTIDYL PEPTIDASE 4; HUMANS; HYPOGLYCEMIC AGENTS; PROTEASE INHIBITORS; PYRIMIDINES; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 77955367308     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmcl.2010.06.063     Document Type: Article

References (23)

1. Diabetes Facts and Figures. International Diabetes Foundation, October 6, 2009. http://www.idf.org/Facts-and-Figures.
2. S. Wild, C. Roglic, A. Green, R. Sicree, and H. King Diabetes 27 2004 1047
3. For latest information, please visit the website of World Health Organization at http://www.who.int/diabetes/facts/world-figures/en/.
4. S.A. Ross, E.A. Gulve, and M. Wang Chem. Rev. 104 2004 1255
5. M. Rizzo, A.A. Rizvi, G.A. Spinas, G.B. Rini, and K. Berneis Expert Opin. Invest. Drugs 18 2009 1495
6. J.J. Holst, and C.J. Deacon Diabetes 47 1998 1663
7. G.R. Lankas, B. Leiting, R.S. Roy, G.J. Eiermann, M.G. Beconi, T. Biftu, C.C. Chan, S. Edmonson, W.P. Feeney, H. He, D.E. Ippolito, D. Kim, K.A. Lyons, H.O. Ok, R.A. Patel, A.N. Petrov, K.A. Pryor, X. Qian, L. Reigle, A. Woods, J.K. Wu, D. Zaller, X. Zhang, L. Zhu, A.E. Weber, and N.A. Thornberry Diabetes 54 2005 2988
8. B. Ahrén, and T.E. Hughes Endocrinology 146 2005 2055
9. M. Zander, S. Madsbad, J.L. Madsen, and J.J. Holst Lancet 359 2002 824
10. M.A. Nauck, D. Wollschlaeger, J. Werner, J.J. Holst, C. Orskov, W. Creutzfeldt, and B. Williams Diabetologia 39 1996 1546
11. L. Hansen, C.F. Deacon, C. Orskov, and J.J. Holst Endocrinology 140 1999 5356
12. B. Ahrén Expert Opin. Invest. Drugs 15 2006 431
13. D. Kim, L. Wang, M. Beconi, M.H. Fisher, H. He, G.J. Hickey, J.E. Kowalchick, B. Leiting, K. Lyons, F. Marsilio, M.E. McCann, R.A. Patel, A. Petrov, G. Scapin, S.B. Patel, R.S. Roy, J.K. Wu, M.J. Wyvratt, B.B. Zhang, L. Zhu, N.A. Thornberry, and A.E. Weber J. Med. Chem. 48 2005 141
14. D.J. Augeri, J.A. Robl, D.A. Betebenner, D.R. Magnin, A. Khanna, J.G. Robertson, A. Wang, L.M. Simpkins, P. Taunk, Q. Huang, S.P. Han, B. Abboa-Offei, M. Cap, L. Xin, L. Tao, E. Tozzo, G.E. Welzel, D.M. Egan, J. Marcinkeviciene, S.Y. Chang, S.A. Biller, M.S. Kirby, R.A. Parker, and L.G. Hamann J. Med. Chem. 48 2005 5025
15. E. Villhauer, J.A. Brinkman, G.B. Naderi, B.F. Burkey, B.F. Dunning, K. Prasad, B.L. Mangold, M.E. Russell, and T.E. Hughes J. Med. Chem. 46 2003 2774
16. J. Feng, Z. Zhang, M.B. Wallace, J.A. Stafford, S.W. Kaldor, D.B. Kassel, M. Navre, L. Shi, R.J. Skene, T. Asakawa, K. Takeuchi, R. Xu, D.R. Webb, and S.L. Gwaltney J. Med. Chem. 50 2007 2297
17. M. Eckhardt, E. Langkopf, M. Mark, M. Tadayyon, L. Thomas, H. Nar, W. Pfrengle, B. Guth, R. Lotz, P. Sieger, H. Fuchs, and F. Himmelsbach J. Med. Chem. 50 2007 6450
18. H.M.R. Pattzi, S. Pitale, M. Alpizar, C. Bennett, A.M. O'Farrell, J. Li, J.M. Cherrington, H.-P. Guler PHX1149-PROT202 Study Group Diabetes. Obes. Metab. 12 2010 348
19. For other small molecular DPP-IV inhibitors, see: S.H. Havale, and M. Pal Bioorg. Med. Chem. 17 2009 1783 and references cited therein
20. J.A. Settepani, and J.B. Stokes J. Org. Chem. 33 1968 2606
21. D.R. Magnin, J.A. Robl, R.B. Sulsky, D.J. Augeri, Y. Huang, L.M. Simpkins, P.C. Taunk, D.A. Betebenner, J.G. Robertson, B.E. Abboa-Offei, A. Wang, M. Cap, L. Xin, L. Tao, D.F. Sitkoff, M.F. Malley, J.Z. Gougoutas, A. Khanna, Q. Huang, S.P. Han, R.A. Parker, and L.G. Hamann J. Med. Chem. 47 2004 2587
22. T.L. Little, and S.E. Webber J. Org. Chem. 59 1994 7299
23. Oral glucose tolerance test in ob/ob mice. Male 13-14 weeks old ob/ob mice (Jackson Labs) were maintained under constant temperature and humidity conditions, a 12 h:12 h light-dark cycle, and had free access to a 10% fat rodent diet (D1245B Research Diets) and tap water. After an overnight fasting period, animals were dosed orally with vehicle (water) or DPP4 inhibitor (3 and 10 μmol/kg) at -60 min. Two blood samples were collected at -60 and 0 min by tail bleed for glucose and insulin determinations. Glucose (2 g/kg) was then administered orally (at 0 min). Additional blood samples were collected at 15, 30, 60, 90, and 120 min for glucose and insulin determinations. Blood samples were collected into EDTA containing tubes (Sarstedt). Plasma insulin was assayed using a mouse insulin ELISA kit (ALPCO Diagnostics). Data represent the mean of 12-24 mice/group. All procedures were performed according to BMS-IACUC guidelines.